BPC-157 and TB-500

01 · What it is

This guide covers the two compounds administered together. It is not a compound in its own right and has no chemistry of its own: BPC-157 is a synthetic pentadecapeptide, GEPPPGKPADDAGLV, molecular weight approximately 1,419 Da ³; TB-500 is a synthetic N-acetylated heptapeptide, Ac-LKKTETQ, molecular weight approximately 889 Da calculated from its sequence, corresponding to residues 17–23 of thymosin β4 ⁷.

The pairing has been tested as an intervention exactly once. In a 2026 rat Achilles transection-and-repair model, thirty-two animals were randomised to control, BPC-157, TB-500 or both. The result, in the authors’ words, was that “combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone” ¹⁰.

There is a second, weaker line of evidence pointing the same direction. In the only human report in which both peptides were given, a retrospective knee-pain series, twelve patients received BPC-157 alone and four received BPC-157 with thymosin β4. Eleven of twelve in the single-agent group reported significant improvement, against three of four in the combination group ⁶. Four patients cannot support any inference, and the direction is worth noting only because it matches the animal result rather than opposing it.

No published scientific rationale predates the pairing. The two compounds were combined first and tested afterwards, and the only test found no addition. That is the whole evidential position, and everything else in this guide describes what is known about the components separately, and what would need to be done to answer the combination question properly.

As of September 2026 neither compound holds a marketing authorisation from any regulator.

02 · Evidence at a glance

Evidence grade

Preclinical

Studies testing the combination

1, in rats ¹⁰

Animals in the combination arm

8

Result versus either agent alone

No additional benefit ¹⁰

Human studies of the combination

None. One retrospective series included 4 patients given both ⁶

Pharmacokinetic interaction data

None, in any species

Combination toxicology

None

Dose ratios tested

One: BPC-157 10 µg/kg/day and TB-500 60 µg/kg/day, intraperitoneal, 4 weeks ¹⁰

Molecular target, BPC-157

Not identified ^8,12

Molecular target, TB-500

Not identified; the parent protein binds G-actin ¹

Approval status

None, either compound, any jurisdiction

03 · Mechanism of action

The stated rationale, and why it is only a hypothesis

The rationale for combining these two compounds is that they are supposed to act on complementary processes: BPC-157 on angiogenesis, TB-500 on the actin cytoskeleton. Neither half of that claim is as solid as the pairing implies.

BPC-157 and VEGFR2. The best-supported mechanistic account for BPC-157 is that it promotes vessel formation in chorioallantoic membrane and endothelial tube-formation assays and accelerates blood-flow recovery in rat hind-limb ischaemia, with the effect associated with activation and upregulation of vascular endothelial growth factor receptor 2 ⁴. No receptor for BPC-157 has been identified, and reviews describe its mechanism as inferred from downstream changes rather than demonstrated at a binding site ^8,9,12.

TB-500 and actin. The actin-sequestering mechanism belongs to thymosin β4, which binds G-actin stoichiometrically through the β-thymosin/WH2 module ^1,2. Whether the acetylated heptapeptide inherits that function is unresolved: a 2024 study stated that the documented biological functions of this sequence belong to its unacetylated form and that the effects of TB-500 itself have not been documented, and found wound-healing activity in the metabolite Ac-LKKTE rather than in the administered compound ⁷.

What “complementary” would require, and what was found instead

For two agents to be additive, each must produce an effect, and their effects must operate through routes that do not saturate the same downstream step. The single combination experiment was designed to detect exactly that and did not find it. Its authors offered convergence on shared downstream pathways as one possible explanation, while stating explicitly that the hypothesis requires further experimental confirmation ¹⁰. Two other explanations are equally consistent with the data: that the dose ratio tested was wrong, or that one agent contributed little to add to — in that experiment, BPC-157’s own effects did not reach statistical significance while TB-500’s did ¹⁰.

The interaction nobody has measured

No study has examined whether these two peptides interact pharmacokinetically, compete for clearance, or alter each other’s stability in solution or in plasma. TB-500 is known to adsorb substantially to glassware and plasticware, which affects recovery in quantitative work ⁵; whether co-formulation changes that behaviour is unknown. No combination product has been characterised for identity, purity or aggregation.

04 · Key research findings

The one combination study. Thirty-two male Sprague-Dawley rats, approximately 12 weeks old and 330 g, underwent standardised Achilles tendon transection and repair and were randomised into four groups of eight: control, BPC-157 at 10 µg/kg/day, TB-500 at 60 µg/kg/day, and both. Treatment was intraperitoneal, daily, for four weeks, after which tendons went to biomechanical testing or histological evaluation with Bonar and Movin scoring, Sirius red birefringence for collagen organisation, and immunohistochemistry for collagen types I and III ¹⁰.

Findings as reported: maximum load to failure was higher than control in both single-agent groups, reaching significance only for TB-500 (p < 0.05); total Bonar scores were significantly lower than control in the TB-500 group (p = 0.016); total Movin scores were significantly lower in the TB-500 group (p = 0.017) and in the combination group (p = 0.040); collagen type I expression did not differ significantly among groups while type III did; and the combination conferred no additional benefit over either agent alone ¹⁰.

The combination beat the control on one histological measure and beat neither single agent on anything.

How much that study can settle. Bonar and Movin are semiquantitative histological grading systems for tendinopathy: they describe matrix organisation, cellularity and vascularity, not function, and a lower score means tissue architecture closer to normal rather than a clinical outcome. With eight animals per arm the study had limited power to detect a small additive effect.

The honest reading is that no additive benefit was observed under these conditions, not that additivity has been excluded — and no adequately powered interaction study, at more than one dose ratio, over longer than four weeks, has been published or located in registries.

The human observation. A retrospective chart review at a single clinic identified seventeen patients given intra-articular peptide injection for knee pain of mixed cause; sixteen were reached by telephone survey. Twelve had received BPC-157 alone, of whom eleven (91.6%) reported significant improvement. Four had received BPC-157 with thymosin β4, of whom three (75%) reported improvement. No imaging, no control group, no validated instrument ⁶.

This is a four-patient subgroup inside an uncontrolled series, and its only value is that it does not contradict the animal finding.

Everything else attributed to the pairing. No combination work exists in muscle, ligament, gastrointestinal tissue, skin, bone or any other system. Reviews written for orthopaedic and sports medicine audiences list both compounds among those whose reported musculoskeletal benefits are largely unvalidated in human trials, and none identifies combination evidence ^8,11,13,14.

Synergy claims for this pairing have no published source.

05 · Evidence overview

06 · Safety profile

Animal data. The single combination study did not report systemic toxicity outcomes for any arm ¹⁰. For the components: this review identified no repeat-dose toxicology, genotoxicity, reproductive or carcinogenicity study for BPC-157 in the indexed literature, and none of any kind for TB-500. The 2024 metabolite study found no cytotoxicity of TB-500 or its metabolites in fibroblasts, which is a narrow observation in one cell type ⁷.

Human data. None for the combination beyond four patients in a retrospective series that collected safety information by telephone months after injection and reported no adverse events ⁶. That method cannot reliably capture adverse events and was not designed to.

What is genuinely unknown, and what combination specifically adds. Everything unknown about each compound separately applies here, and combination adds a distinct problem: attribution. When two investigational peptides are administered together and something happens, neither the benefit nor the harm can be assigned. That is not a theoretical concern — it is the reason the four-patient human subgroup cannot be interpreted, and the reason the rat study’s null result cannot distinguish pathway convergence from an inadequate dose. Beyond that: no interaction pharmacokinetics, no combined immunogenicity data, no repeat-administration data over any timeframe, and no characterisation of what a co-formulated preparation actually contains.

07 · US regulatory status

Current as of 6 September 2026. Neither compound is approved as a drug in the United States or any other jurisdiction, and neither is a controlled substance. No combination product has been evaluated by any regulator.

Both were placed in category 2 of FDA’s interim bulk drug substances policy in September 2023 — BPC-157, and separately “Thymosin beta-4, fragment (LKKTETQ), also known as TB-500.” As of FDA’s page dated 22 April 2026 both entries appear in the table of substances nominated but subsequently withdrawn by the nominators ¹⁵. Both were reviewed individually by FDA’s Pharmacy Compounding Advisory Committee on 23 July 2026 — BPC-157 for ulcerative colitis, TB-500 for wound healing ¹⁶. No combination was on that agenda. Advisory committee recommendations are non-binding and nothing has been added to the 503A Bulks List as a result.

Under the World Anti-Doping Code, growth factors affecting muscle, tendon or ligament regeneration are prohibited at all times, and substances not approved by any governmental regulatory health authority for human therapeutic use fall within category S0.

08 · Limitations of the evidence

1. One study is not an evidence base. Every claim about this pairing rests on a single exploratory animal experiment with eight rats per arm, four weeks of treatment, and one dose level of each compound ¹⁰. No replication exists.
2. That study’s combination result was null. The authors state that combining the two conferred no additional benefit over either agent alone ¹⁰. A null result in an underpowered study does not exclude a small effect, but it is the only direct evidence available and it does not support the pairing.
3. No human has been studied on the combination in any controlled design. The four patients who received both peptides sit inside an uncontrolled retrospective series with a subjective endpoint, and their response rate was numerically lower than the single-agent group in the same series ⁶.
4. Combination effects cannot be inferred from component evidence. Even if both compounds worked individually — and BPC-157’s effects did not reach significance in the one experiment that tested both ¹⁰ — additivity would still require demonstration. Pharmacology does not permit adding results across separate studies.
5. The test article in the only combination study was not characterised. The paper describes its TB-500 as “synthetic thymosin beta-4 (TB-500)” ¹⁰, conflating two substances that the identity literature has distinguished since 2012 ⁷. What was administered is therefore uncertain.
6. Component safety records are incomplete in different ways. BPC-157 has no carcinogenicity data in any species; TB-500 has no toxicology of any kind. Two incomplete records do not combine into an adequate one, and no study has examined the pair together.
7. Attribution is structurally impossible in combination use. Any effect observed when two uncharacterised peptides are given together belongs to an unknown — the first compound, the second, an interaction, or neither. This limitation cannot be designed around except by studying the agents separately first, which for TB-500 has essentially not been done.

09 · References

1. De La Cruz EM, Ostap EM, Brundage RA, Reddy KS, Sweeney HL, Safer D. Thymosin-beta(4) changes the conformation and dynamics of actin monomers. Biophys J. 2000;78(5):2516–2527.

   PMID 10777749 ↗

2. Carlier MF, Hertzog M, Didry D, et al. Structure, function, and evolution of the beta-thymosin/WH2 (WASP-Homology2) actin-binding module. Ann N Y Acad Sci. 2007;1112:67–75.

   PMID 17947587 ↗

3. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des. 2014;20(7):1126–1135.

   PMID 23755725 ↗

4. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323–333.

   PMID 27847966 ↗

5. Judák P, Van Eenoo P, Deventer K. Adsorption effects of the doping relevant peptides Insulin Lispro, Synachten, TB-500 and GHRP 5. Anal Biochem. 2017;537:69–71.

   PMID 28887173 ↗

6. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8–13.

   PMID 34324435 ↗

7. Rahaman KA, Muresan AR, Min H, Son J, Han HS, Kang MJ, Kwon OS. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B Analyt Technol Biomed Life Sci. 2024;1235:124033.

   PMID 38382158 ↗

8. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485–495.

   PMID 40756949 ↗

9. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025;18(12):611–619.

   PMID 40789979 ↗

10. Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822–837.

    PMID 42542926 ↗

11. Mayfield CK, Bolia IK, Feingold CL, et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med. 2026;54(1):223–229.

    PMID 41476424 ↗

12. Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics. 2026;18(5):625.

    PMID 42198317 ↗

13. Rahman OF, Lee SJ, Seeds WA. Therapeutic peptides in orthopaedics: applications, challenges, and future directions. J Am Acad Orthop Surg Glob Res Rev. 2026;10(1):e25.00236.

    PMID 41490200 ↗

14. Tewari K, Liu TP, Im C, et al. Peptide supplements and their therapeutic applications in sports medicine. Am J Sports Med. 2026; online ahead of print.

    PMID 42578445 ↗

15. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Page current as of 22 April 2026. Regulatory document; no PMID.

    Source ↗

16. US Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Docket FDA-2025-N-6895. Regulatory document; no PMID.

    Source ↗